Eisai is committed to supporting patient access by helping with your reimbursement questions. With this in mind, the ALOXI® (palonosetron HCI injection) Reimbursement site has been designed to provide healthcare professionals with information related to the insurance reimbursement environment for ALOXI®.
ALOXI® (palonosetron HCl) injection 0.25 mg is indicated in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy, and the prevention of acute nausea and vomiting associated with initial and repeat courses of highly emetogenic chemotherapy.
Professional Important Safety Information:
- ALOXI® is contraindicated in patients known to have hypersensitivity to the drug of any of its components
- Hypersensitivity reactions, including anaphylaxis, have been reported with or without known hypersensitivity to other 5-HT3 receptor antagonists
- Most commonly reported adverse reactions in chemotherapy-induced nausea and vomiting include headache (9%) and constipation (5%)
For more information about ALOXI® please see full Prescribing Information.